UNSPSC 51182210: Dinoprost

This classification denotes a prostaglandin analogue with the molecular formula C20H34O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B7IN85G1HY, chemically known as (5z,13e)-(15s)-9-alpha,11-alpha,15-trihydroxyprosta-5,13-dienoate but generally known as dinoprost, which bears US NIH Compound Identifier 160. European Medicines Agency schedules Dinoprost in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07194MIG.

UNSPSC 51182210 Dinoprost, a Commodity code, covers pharmaceutical products supplied through state and local cooperative purchasing vehicles, with recent activity focused on multi-source generic pharmaceuticals and over-the-counter products procured for distribution across participating government facilities. State and local governments buy dinoprost and related prostaglandin analogs through cooperative purchasing arrangements that consolidate demand across multiple jurisdictions and establish master contracts with manufacturers, allowing member agencies—state departments, county health systems, and municipal facilities—to order at negotiated rates. The work involves manufacturers meeting regulatory compliance (cGMP and Drug Supply Chain Security Act certification), maintaining relationships with authorized pharmaceutical wholesalers, and providing detailed product specifications including National Drug Codes, strength, dosage form, and packaging configurations for inventory management and clinical use.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued the primary recent opportunity—a Request for Proposal (RFP) for generic multi-source pharmaceuticals and OTC products posted January 20, 2026, with proposals due March 26, 2026. MMCAP serves participating state and local government facilities across Minnesota and Oregon. Vendors must supply through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), maintain contractual relationships with at least two, and provide flexible pricing (flat price, net price formats, or WAC-minus structures). The contract term runs two years for new vendors with optional extensions, effective July 1, 2026, with performance penalties ranging from $200 to $1,500 per violation for late reporting or missed onboarding timelines. Evaluation emphasizes price competitiveness (75 percent weight) alongside compliance with administrative fee data formats, EDI capability, insurance requirements ($5 million commercial general liability per occurrence, $2 million network security and privacy liability, $2 million professional liability), and FDA expiration-dating standards.